Levomilnacipran

Palmer, Emma; Binns, Lindsey N.; Carey, Heather

doi:10.1177/1060028014535074

Cited by 10 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Future larger studies designed to evaluate patients with recurrent or treatment-resistant depression are necessary. Fourth, levomilnacipran ER appears to display greater noradrenergic activity at a lower dose and increasing effects on serotonergic neurotransmission as the dose increases 28. However, our study did not detect dose–response effects, since most of the clinical studies used flexible dosing.…”

Section: Discussionmentioning

confidence: 57%

Efficacy and safety of multiple doses of levomilnacipran extended-release for the treatment of major depressive disorder

Huang¹,

Zhong²,

Ye³

et al. 2016

NDT

View full text Add to dashboard Cite

ObjectiveThe aim of this meta-analysis was to evaluate the efficacy and safety of levomilnacipran extended-release (ER) in the treatment of major depressive disorder (MDD).MethodsRandomized controlled trials were searched by electronic databases. Unpublished data were also searched by the relevant websites. Weighted mean difference (WMD) and risk ratio (RR) with 95% confidence interval (CI) were calculated and pooled using fixed-effects model or random-effects model.ResultsFive randomized placebo-controlled trials including 2,637 patients were analyzed. Compared with placebo, levomilnacipran ER had a greater reduction in the Montgomery–Åsberg Depression Rating Scale (MADRS) total score and Sheehan Disability Scale (SDS) total score (MADRS: WMD −3.49 [95% CI −4.28, −2.70; P<0.00001]; SDS: WMD −2.41 [95% CI −3.05, −1.77; P<0.00001]). Significantly more patients in levomilnacipran ER achieved MADRS response rate (RR 1.35 [95% CI 1.23, 1.47; P<0.00001]) and MADRS remission rate (RR 1.30 [95% CI 1.06, 1.59; P=0.01]). In terms of safety, more patients discontinued due to adverse events (AEs) in levomilnacipran ER compared with placebo (RR 3.15 [95% CI 2.26, 4.39; P<0.00001]), but it was generally well tolerated in each eligible trial. The most common AEs were nausea, delay in ejaculation, erectile dysfunction, tachycardia, headache and increase in heart rate.ConclusionLevomilnacipran ER is a safe and effective short-term treatment for MDD (≤10 weeks). Long-term and head-to-head trials comparing levomilnacipran ER with other antidepressants are needed to confirm the conclusion.

show abstract

Section: Discussionmentioning

confidence: 57%

Efficacy and safety of multiple doses of levomilnacipran extended-release for the treatment of major depressive disorder

Huang¹,

Zhong²,

Ye³

et al. 2016

NDT

View full text Add to dashboard Cite

show abstract

“…venlafaxine, desvenlafaxine, duloxetine, levomilnacipran), bupropion, and mirtazapine have minimal anticholinergic effects. 36,37 Moclobemide exhibits a safety profile, including a lack of anticholinergic and sedative effects, as well as being unlikely to cause a hypertensive crisis when combined with tyramine diets, making it advantageous for older patients. 8 Buspirone, a partial 5HT 1A agonist, is approved for anxiety disorders and short-term anxiety relief.…”

Section: Common Causes Of Inadequate Care Of Older Adults With Late-l...mentioning

confidence: 99%

Optimizing treatment for older adults with depression

Srifuengfung,

Pennington,

Lenze

2023

Therapeutic Advances in Psychopharmacology

View full text Add to dashboard Cite

This review presents a comprehensive guide for optimizing medication management in older adults with depression within an outpatient setting. Medication optimization involves tailoring the antidepressant strategy to the individual, ensuring the administration of appropriate medications at optimal dosages. In the case of older adults, this process necessitates not only adjusting or changing antidepressants but also addressing the concurrent use of inappropriate medications, many of which have cognitive side effects. This review outlines various strategies for medication optimization in late-life depression: (1) Utilizing the full dose range of a medication to maximize therapeutic benefits and strive for remission. (2) Transitioning to alternative classes (such as a serotonin and norepinephrine reuptake inhibitor [SNRI], bupropion, or mirtazapine) when first-line treatment with selective serotonin reuptake inhibitors [SSRIs] proves inadequate. (3) Exploring augmentation strategies like aripiprazole for treatment-resistant depression. (4) Implementing measurement-based care to help adjust treatment. (5) Sustaining an effective antidepressant strategy for at least 1 year following depression remission, with longer durations for recurrent episodes or severe presentations. (6) Safely discontinuing anticholinergic medications and benzodiazepines by employing a tapering method when necessary, coupled with counseling about the benefits of stopping them. Additionally, this article explores favorable medications for depression, as well as alternatives for managing anxiety, insomnia, allergy, overactive bladder, psychosis, and muscle spasm in order to avoid potent anticholinergics and benzodiazepines.

show abstract

“…This unique characteristic distinguishes milnacipran from other SNRIs that exhibit a greater affinity for serotonin reuptake [ 4 , 5 ], although, in vivo, milnacipran shows comparable affinity for both serotonin and norepinephrine transporters [ 6 ]. Notably, levomilnacipran, which is an enantiomer of milnacipran ((1S,2R)-milnacipran) and is deemed to be more active than the racemic mixture, is available in the market as an extended-release capsule formulation and is approved by the FDA for MDD but not fibromyalgia [ 7 , 8 ].…”

Section: Introductionmentioning

confidence: 99%

Systemic and Brain Pharmacokinetics of Milnacipran in Mice: Comparison of Intraperitoneal and Intravenous Administration

Bagchi,

Nozohouri,

Ahn

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

Milnacipran is a dual serotonin and norepinephrine reuptake inhibitor, clinically used for the treatment of major depression or fibromyalgia. Currently, there are no studies reporting the pharmacokinetics (PK) of milnacipran after intraperitoneal (IP) injection, despite this being the primary administration route in numerous experimental studies using the drug. Therefore, the present study was designed to investigate the PK profile of IP-administered milnacipran in mice and compare it to the intravenous (IV) route. First a liquid chromatography–mass spectrometry (LC-MS/MS) method was developed and validated to accurately quantify milnacipran in biological samples. The method was used to quantify milnacipran in blood and brain samples collected at various time-points post-administration. Non-compartmental and PK analyses were employed to determine key PK parameters. The maximum concentration (Cmax) of the drug in plasma was at 5 min after IP administration, whereas in the brain, it was at 60 min for both routes of administration. Curiously, the majority of PK parameters were similar irrespective of the administration route, and the bioavailability was 92.5% after the IP injection. These findings provide insight into milnacipran’s absorption, distribution, and elimination characteristics in mice after IP administration for the first time and should be valuable for future pharmacological studies.

show abstract

Levomilnacipran

Cited by 10 publications

References 23 publications

Efficacy and safety of multiple doses of levomilnacipran extended-release for the treatment of major depressive disorder

Efficacy and safety of multiple doses of levomilnacipran extended-release for the treatment of major depressive disorder

Optimizing treatment for older adults with depression

Systemic and Brain Pharmacokinetics of Milnacipran in Mice: Comparison of Intraperitoneal and Intravenous Administration

Contact Info

Product

Resources

About